NxThera pioneered its Convective Water Vapor Energy (WAVE®) technology to treat a variety of endourological conditions beginning with BPH, which was cleared by FDA in August 2015. The Rezūm® System applies the thermal energy stored in sterile water vapor to convectively deliver targeted, precise treatments to the enlarged prostate tissue in a simple transurethral procedure. Three-year clinical data demonstrates sustained improvements in LUTS, urine flow, quality of life, and preservation of sexual function. The company is conducting advanced development and clinical research to potentially expand application of its technology to include the targeted treatment of cancerous prostate, kidney and bladder tissue as well as OAB.
For more information about Rezūm, the FDA cleared technology to treat BPH, visit www.rezum.com.